Audited Supplier
250ml
Surgery
Elderly, Children, Adult
Liquid
Inorganic Chemicals
Chemical Synthesis
H20050085
Huaren
Carton
250ml
China
Product Description
Drug name :Isosorbide Mononitrate Sodium Chloride Injection
Character:This product is colorless clear liquid
Indications:
Electrolyte supplements. It can be used for the adjuvant treatment of hypokalemia, arrhythmias caused by digitalis poisoning (mainly ventricular arrhythmias), sequelae of myocarditis, congestive heart failure, and myocardial infarction.
Specification:
| Potassium Magnesium Aspartate and Glucose Injection | 250ml:L-Aspartate 0.85g Potassium0.114g Magnesium 0.042g Glucose12.5g | Non PVC soft bags |
Founded in May 1998, Huaren Pharmaceutical is a modern pharmaceutical and health industry group integrating R&D, production and sales, focusing on medicine, health, medical equipment and medical services.
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.
After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.
After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".
Pharmaceutical packaging materials,Rubber stoppers and APIs are self-produced and self-sold, the price is lower and the quality is more guaranteed.
